NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

癲癇治療藥的全球市場:2020年∼2024年

Global Epilepsy Drugs Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 973459
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
癲癇治療藥的全球市場:2020年∼2024年 Global Epilepsy Drugs Market 2020-2024
出版日期: 2020年11月12日內容資訊: 英文 120 Pages
簡介

全球癲癇治療藥的市場規模在2020年∼2024年間,預測將成長到21億3000萬美元,在預測期間中預計將以5%的年複合成長率增長。

市場成長的主要因素有癲癇的盛行率增加和患者的意識的提升。

本報告提供癲癇治療藥的世界市場調查,提供市場形勢和規模,波特的五力分析,各類型,病因等的市場區隔,客戶和各地區形勢,業者情勢,供應商分析等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

市場區隔:各類型

  • 市場區隔
  • 各類型比較
  • 窄頻譜的藥物:市場規模與預測(2019年∼2024年)
  • 寬頻譜的藥物:市場規模與預測(2019年∼2024年)
  • 各類型的市場機會

市場區隔:各病因

  • 遺傳的(原因性)病因
  • 結構的病因
  • 代謝性病因
  • 免疫性病因
  • 感染性病因
  • 病因不明

市場區隔:各發病年齡

  • 新生兒/幼兒
  • 兒童
  • 青年/成人
  • 可變年齡

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2019年∼2024年)
  • 歐洲:市場規模與預測(2019年∼2024年)
  • 亞洲:市場規模與預測(2019年∼2024年)
  • 其他地區:市場規模與預測(2019年∼2024年)
  • 主要國家
  • 各地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abbott Laboratories
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

附錄

目錄
Product Code: IRTNTR45677

Technavio has been monitoring the epilepsy drugs market and it is poised to grow by $ 2.13 bn during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on epilepsy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of epilepsy and increasing patient awareness. In addition, increasing prevalence of epilepsy is anticipated to boost the growth of the market as well.

The epilepsy drugs market analysis includes the type segment, etilogy segment, age of onset segment and geographical landscapes.

Technavio's epilepsy drugs market is segmented as below:

By Type

  • Narrow spectrum drugs
  • Broad spectrum drugs

By Etiology

  • Genetic etiology
  • Structural etiology
  • Metabolic etiology
  • Immune etiology
  • Infectious etiology
  • Unknown etiology

By Age of onset

  • Neonatal/infantile
  • Childhood
  • Adolescents/adults
  • Variable age

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing use of specific and sensitive diagnostic modalities as one of the prime reasons driving the epilepsy drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our epilepsy drugs market covers the following areas:

  • Epilepsy drugs market sizing
  • Epilepsy drugs market forecast
  • Epilepsy drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy drugs market vendors that include Abbott Laboratories, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the epilepsy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Narrow spectrum drugs - Market size and forecast 2019-2024
  • Broad spectrum drugs - Market size and forecast 2019-2024
  • Market opportunity by Type

Segmentation by Etiology

  • Genetic etiology
  • Structural etiology
  • Metabolic etiology
  • Immune etiology
  • Infectious etiology
  • Unknown etiology

Segmentation by Age of Onset

  • Neonatal/infantile
  • Childhood
  • Adolescents/adults
  • Variable age

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Narrow spectrum drugs - Market size and forecast 2019-2024 ($ million)
  • 24: Narrow spectrum drugs - Year-over-year growth 2019-2024 (%)
  • 25: Broad spectrum drugs - Market size and forecast 2019-2024 ($ million)
  • 26: Broad spectrum drugs - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ million)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: Asia - Market size and forecast 2019-2024 ($ million)
  • 36: Asia - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Abbott Laboratories - Overview
  • 48: Abbott Laboratories - Business segments
  • 49: Abbott Laboratories - Key offerings
  • 50: Abbott Laboratories - Key customers
  • 51: Abbott Laboratories - Segment focus
  • 52: Eisai Co. Ltd. - Overview
  • 53: Eisai Co. Ltd. - Business segments
  • 54: Eisai Co. Ltd. - Key offerings
  • 55: Eisai Co. Ltd. - Key customers
  • 56: Eisai Co. Ltd. - Segment focus
  • 57: GlaxoSmithKline Plc - Overview
  • 58: GlaxoSmithKline Plc - Business segments
  • 59: GlaxoSmithKline Plc - Key offerings
  • 60: GlaxoSmithKline Plc - Key customers
  • 61: GlaxoSmithKline Plc - Segment focus
  • 62: Johnson & Johnson - Overview
  • 63: Johnson & Johnson - Business segments
  • 64: Johnson & Johnson - Key offerings
  • 65: Johnson & Johnson - Key customers
  • 66: Johnson & Johnson - Segment focus
  • 67: Mylan NV - Overview
  • 68: Mylan NV - Business segments
  • 69: Mylan NV - Key offerings
  • 70: Mylan NV - Key customers
  • 71: Mylan NV - Segment focus
  • 72: Novartis AG - Overview
  • 73: Novartis AG - Business segments
  • 74: Novartis AG - Key offerings
  • 75: Novartis AG - Key customers
  • 76: Novartis AG - Segment focus
  • 77: Pfizer Inc. - Overview
  • 78: Pfizer Inc. - Business segments
  • 79: Pfizer Inc. - Key offerings
  • 80: Pfizer Inc. - Key customers
  • 81: Pfizer Inc. - Segment focus
  • 82: Sanofi - Overview
  • 83: Sanofi - Business segments
  • 84: Sanofi - Key offerings
  • 85: Sanofi - Key customers
  • 86: Sanofi - Segment focus
  • 87: Teva Pharmaceutical Industries Ltd. - Overview
  • 88: Teva Pharmaceutical Industries Ltd. - Business segments
  • 89: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 90: Teva Pharmaceutical Industries Ltd. - Key customers
  • 91: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 92: UCB SA - Overview
  • 93: UCB SA - Product and service
  • 94: UCB SA - Key offerings
  • 95: UCB SA - Key customers
  • 96: UCB SA - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations